Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
67 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Community-Acquired Bacterial Pneumonia - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Community-Acquired Bacterial Pneumonia - Pipeline Review, H2 2014', provides an overview of the Community-Acquired Bacterial Pneumonia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Community-Acquired Bacterial Pneumonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Community-Acquired Bacterial Pneumonia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Community-Acquired Bacterial Pneumonia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Community-Acquired Bacterial Pneumonia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Community-Acquired Bacterial Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Community-Acquired Bacterial Pneumonia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Community-Acquired Bacterial Pneumonia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Community-Acquired Bacterial Pneumonia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Community-Acquired Bacterial Pneumonia Overview 7 Therapeutics Development 8 Pipeline Products for Community-Acquired Bacterial Pneumonia - Overview 8 Pipeline Products for Community-Acquired Bacterial Pneumonia - Comparative Analysis 9 Community-Acquired Bacterial Pneumonia - Therapeutics under Development by Companies 10 Community-Acquired Bacterial Pneumonia - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Community-Acquired Bacterial Pneumonia - Products under Development by Companies 14 Community-Acquired Bacterial Pneumonia - Companies Involved in Therapeutics Development 15 Cubist Pharmaceuticals, Inc. 15 Furiex Pharmaceuticals, Inc. 16 Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. 17 Melinta Therapeutics, Inc 18 Nabriva Therapeutics AG 19 Tetraphase Pharmaceuticals Inc. 20 Community-Acquired Bacterial Pneumonia - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 acorafloxacin - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 BC-3781 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 DBAF-301 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 faropenem medoxomil - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 radezolid - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecules to Inhibit 23S Ribosomal RNA for Infections - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 solithromycin - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 TP-271 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 TP-834 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Community-Acquired Bacterial Pneumonia - Recent Pipeline Updates 45 Community-Acquired Bacterial Pneumonia - Dormant Projects 56 Community-Acquired Bacterial Pneumonia - Discontinued Products 57 Community-Acquired Bacterial Pneumonia - Product Development Milestones 58 Featured News & Press Releases 58 Sep 25, 2014: Cempra Completes Enrollment of Solitaire-Oral Phase 3 Trial 58 Feb 20, 2014: Cempra Initiates Solithromycin Pediatric Program 58 Dec 16, 2013: Cempra Provides Update on Clinical Development of Solithromycin 59 Sep 10, 2013: Cempra to Present Data at ICAAC on Solithromycin's Activity Against a Broad Range of Pathogens Including Four Proposed or Designated by the Food and Drug Administration as Qualified Infectious Disease Pathogens Under the Generating Antibiotic Incentives Now Act 60 Sep 06, 2013: Cempra's Solithromycin Receives Qualified Infectious Disease Product Designation From the U.S. Food and Drug Administration 62 Jun 13, 2013: Cempra Provides Guidance On Phase III Clinical Program Required For Regulatory Approval Of Solithromycin For Community-Acquired Bacterial Pneumonia 62 May 28, 2013: Cempra Receives $58m Contract To Develop Antibiotic For Pediatric Use And Biodefense From BARDA 63 May 20, 2013: Cempra Presents Post-Phase II Analysis Of Solithromycin's Efficacy And Safety Results From Patients With Community Acquired Bacterial Pneumonia 64 Apr 29, 2013: Tetraphase Pharma Announces Presentation Of Data On Preclinical Candidate TP-271 At ECCMID 2013 64 Dec 19, 2012: Cempra Announces Initiation Of Oral Solithromycin Global Phase III Clinical Trial In Patients With Community-acquired Bacterial Pneumonia 65 Appendix 66 Methodology 66 Coverage 66 Secondary Research 66 Primary Research 66 Expert Panel Validation 66 Contact Us 67 Disclaimer 67
List of Tables Number of Products under Development for Community-Acquired Bacterial Pneumonia, H2 2014 8 Number of Products under Development for Community-Acquired Bacterial Pneumonia - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 10 Comparative Analysis by Late Stage Development, H2 2014 11 Comparative Analysis by Clinical Stage Development, H2 2014 12 Comparative Analysis by Early Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Community-Acquired Bacterial Pneumonia - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 15 Community-Acquired Bacterial Pneumonia - Pipeline by Furiex Pharmaceuticals, Inc., H2 2014 16 Community-Acquired Bacterial Pneumonia - Pipeline by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., H2 2014 17 Community-Acquired Bacterial Pneumonia - Pipeline by Melinta Therapeutics, Inc, H2 2014 18 Community-Acquired Bacterial Pneumonia - Pipeline by Nabriva Therapeutics AG, H2 2014 19 Community-Acquired Bacterial Pneumonia - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2014 20 Assessment by Monotherapy Products, H2 2014 21 Number of Products by Stage and Target, H2 2014 23 Number of Products by Stage and Mechanism of Action, H2 2014 25 Number of Products by Stage and Route of Administration, H2 2014 27 Number of Products by Stage and Molecule Type, H2 2014 29 Community-Acquired Bacterial Pneumonia Therapeutics - Recent Pipeline Updates, H2 2014 45 Community-Acquired Bacterial Pneumonia - Dormant Projects, H2 2014 56 Community-Acquired Bacterial Pneumonia - Discontinued Products, H2 2014 57
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
